AFT Pharmaceuticals - Softer H1 on one-offs; recovery expected in H2
AFT Pharmaceuticals reported H125 revenues of NZ$86.7m, a 3.7% y-o-y increase, albeit lower than expected due to one-off factors such as inventory...
439 Views
AFT Pharmaceuticals - 1H25 Result; No Pain, No Gain
Following a weak update three weeks ago, AFT Pharmaceuticals' (AFT) 1H25 result had few surprises and we have again materially downgraded our...
452 Views
AFT Pharmaceuticals - H125 profitability weighed down by one-offs
AFT Pharmaceuticals has released a trading update ahead of its H125 results, expecting to report a c NZ$2m operating loss for the period ending...
288 Views
AFT Pharmaceuticals - Maxigesic IV reaches the Chinese shores
AFT Pharmaceuticals has taken another major step in extending its international footprint, with the signing of an exclusive license agreement for...
399 Views
AFT Pharmaceuticals - Hikma partnership expands to include Combogesic
AFT Pharmaceuticals has expanded its licensing partnership with Hikma in the US to include distribution of the recently launched Combogesic tablets...
513 Views